Preventing Cancer Relapse by Targeting the Cells Chemotherapy
Leaves Behind.

A dragonfruit based nutraceutical designed to work alongside chemotherapy and directly target cancer stem cells in Triple Negative Breast Cancer.

Talk to Us

Figure B

Hazard Rate for Distant Recurrence

Source: Adapted from Dent et al., 2007 — Hover over the chart to explore data points

Despite Chemotherapy, 50% of TNBC Patients Relapse.

Even after the tumor is removed, hidden cancer stem cells (CSCs) remain. They are resistant, adaptive, and capable of regenerating tumors, even after successful treatment.

Dragoncure exists to address this root cause of recurrence, helping patients move beyond temporary remission toward lasting protection against relapse.

Why Current Treatments Fall Short

Existing approaches often manage symptoms and tumor burden without addressing the cells most likely to drive recurrence.

Highly Toxic

Aggressive regimens can burden quality of life while targeting disease.

Extremely Expensive

Cost and access barriers leave many patients without optimal options.

Symptoms Only

Many approaches focus on bulk tumor burden, not the cells that drive recurrence.

Innaccessible

Innovation does not reach every community equally.

A Multi-Target Approach To Prevent Relapse

DragonCure is built on science that targets the biological mechanisms driving cancer stem cell survival and chemotherapy resistance.

Targets Cancer Stem Cell Pathways

Disrupts key biological mechanisms that allow CSCs to survive and regenerate.

Enhances Chemotherapy Sensitivity

Helps make resistant cancer cells more responsive to treatment.

Maintains a Non-Toxic Profile

Designed to avoid damage to healthy cells in tested models.

Backed By Leading Innovation Partners & Supporters

Ready to Prevent Relapse & Save Lives?

Whether you're a patient willing to participate in our clinical trails or an investor interested in the future of oncology, we would love to hear from you!

For Patients

Join our waitlist to stay informed about clinical progress and availability.

Join Waitlist